근이영양증 치료 시장 : 치료법별, 질환별, 최종사용자별, 지역별

Muscular Dystrophy Treatment Market is estimated to be valued at USD 5.22 billion in 2026 and is expected to reach USD 10.83 billion by 2033, growing at a compound annual growth rate (CAGR) of 11.0% from 2026 to 2033.

The global muscular dystrophy treatment market covers a broad set of treatment type categories, including Gene Therapy, Exon-Skipping Therapeutics, and Corticosteroids, used across applications such as Duchenne Muscular Dystrophy, Becker Muscular Dystrophy, and Limb-Girdle Muscular Dystrophy. Demand is supported by adoption among Hospitals, and Specialty Clinics and the need for more efficient, reliable solutions. Continued technological advancement and rising end-user requirements are shaping the growth of this market.

Market Dynamics:

Growing adoption across Duchenne Muscular Dystrophy, and Becker Muscular Dystrophy, rising end-user demand, and a continued focus on improving efficiency and performance are major factors expected to drive growth of the global muscular dystrophy treatment market. A wider range of available options is making these solutions accessible to a broader base of users.

For instance, companies are expanding their portfolios to address evolving requirements across Hospitals, and Specialty Clinics. Moreover, increasing investment in innovation and new technology integration is expected to create new growth opportunities for market players over the forecast period.

Key features of the study:

• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global muscular dystrophy treatment market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
• Key companies covered as a part of this study include Sarepta Therapeutics, PTC Therapeutics, BioMarin Pharmaceutical, Roche Holding AG, Pfizer Inc., Novartis AG, Catalent Inc., Solid Biosciences, Audentes Therapeutics (Astellas Pharma subsidiary), and Summit Therapeutics, among others.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
• The global muscular dystrophy treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global muscular dystrophy treatment market.

Detailed Segmentation:

• Global Muscular Dystrophy Treatment Market, By Treatment Type (Revenue, USD Bn, 2021 - 2033)
• Gene Therapy
• Exon-Skipping Therapeutics
• Corticosteroids
• Anti-inflammatory Drugs
• Others
• Global Muscular Dystrophy Treatment Market, By Disease Type (Revenue, USD Bn, 2021 - 2033)
• Duchenne Muscular Dystrophy
• Becker Muscular Dystrophy
• Limb-Girdle Muscular Dystrophy
• Facioscapulohumeral Muscular Dystrophy
• Others
• Global Muscular Dystrophy Treatment Market, By End User (Revenue, USD Bn, 2021 - 2033)
• Hospitals
• Specialty Clinics
• Homecare Settings
• Research Institutes
• Others
• Regional Insights (Revenue, USD Bn, 2021 - 2033)
• North America
  • U.S.
  • Canada
• Latin America
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
• Europe
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
• Middle East
  • GCC Countries
  • Israel
  • Rest of Middle East
• Africa
  • South Africa
  • North Africa
  • Central Africa
• Company Profiles:
• Sarepta Therapeutics*
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Recent Developments/Updates
  • Strategies
• PTC Therapeutics
• BioMarin Pharmaceutical
• Roche Holding AG
• Pfizer Inc.
• Novartis AG
• Catalent Inc.
• Solid Biosciences
• Audentes Therapeutics (Astellas Pharma subsidiary)
• Summit Therapeutics

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Treatment Type
  • Market Snapshot, By Disease Type
  • Market Snapshot, By End User
  • Market Snapshot, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Market Opportunities
• Impact Analysis
• Recent Product Launches
• Epidemiology
• Merger, Acquisition, and Collaborations
• Regulatory Scenario
• Key Developments
• PEST Analysis
• Partnership Scenario
• Brand and Pricing Analysis
• Distributors Landscape
• Porters Analysis
• Technological Advancements
• Key Developments
• Market Trend
• Future Prospective
• Top Market Players by Revenue

4. Muscular Dystrophy Treatment Market, By Treatment Type, 2026-2033, (US$ Million)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022-2033
  • Segment Trends
• Gene Therapy
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Million)
• Exon-Skipping Therapeutics
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Million)
• Corticosteroids
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Million)
• Anti-inflammatory Drugs
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Million)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Million)

5. Muscular Dystrophy Treatment Market, By Disease Type, 2026 - 2033, (US$ Million)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022-2033
  • Segment Trends
• Duchenne Muscular Dystrophy
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Million)
• Becker Muscular Dystrophy
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Million)
• Limb-Girdle Muscular Dystrophy
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Million)
• Facioscapulohumeral Muscular Dystrophy
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Million)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Million)

6. Muscular Dystrophy Treatment Market, By End User, 2026 - 2033, (US$ Million)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022-2033
  • Segment Trends
• Hospitals
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Million)
• Specialty Clinics
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Million)
• Homecare Settings
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Million)
• Research Institutes
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Million)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Million)

7. Muscular Dystrophy Treatment Market, By Region, 2026 - 2033, (US$ Million)

• Introduction
  • Market Share Analysis, By Region, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, For Regions, 2022-2033
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2026 - 2033, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2026 - 2033, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2026 - 2033, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (US$ Million)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2026 - 2033, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2026 - 2033, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2026 - 2033, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (US$ Million)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2026 - 2033, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2026 - 2033, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2026 - 2033, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (US$ Million)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Benelux
    • Denmark
    • Norway
    • Sweden
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2026 - 2033, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2026 - 2033, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2026 - 2033, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (US$ Million)
    • China
    • Taiwan
    • India
    • Japan
    • Indonesia
    • Malaysia
    • Philippines
    • Singapore
    • Australia
    • South Korea
    • Rest of Asia Pacific
• Middle East & Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2026 - 2033, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2026 - 2033, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2026 - 2033, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (US$ Million)
    • Bahrain
    • Kuwait
    • Oman
    • Qatar
    • Saudi Arabia
    • UAE
    • Israel
    • South Africa
    • North Africa
    • Central Africa
    • Rest of Middle East

8. Competitive Landscape

• Sarepta Therapeutics
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• PTC Therapeutics
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• BioMarin Pharmaceutical
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Roche Holding AG
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Pfizer Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Novartis AG
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Catalent Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Solid Biosciences
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Audentes Therapeutics (Astellas Pharma subsidiary)
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Summit Therapeutics
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies

9. Section

• Research Methodology
• About Us